久久久国产一区二区_欧美在线小视频_高清一区二区三区_久久综合久久久_成人久久久久久久久_亚洲精品视

荷蘭arGEN-X
arGEN-X公司是一家荷蘭生物制藥公司，專注于開發(fā)人源化抗體藥物，核心技術(shù)是其專有的抗體制備平臺技術(shù)。該技術(shù)平臺產(chǎn)生的單克隆抗體，與人類種系有同源性，是靶向治療人類疾病的好工具

 Innovative technology at the core of our transforming role in the human therapeutic antibody space. The SIMPLE Antibody? platform is a limitless source of extremely high quality human antibodies which modulate the function of any disease target, including complex receptors and highly conserved targets. Unprecedented choice of antibody leads with intrinsic drug qualities dramatically increases the efficiency of antibody discovery and success in development.
Proof of the outstanding productivity of our platform is the speed at which we are progressing our pipeline of five therapeutic antibody programs, addressing cancer, autoimmune and inflammatory indications, into preclinical development. Every human antibody in our pipeline has been generated in vivo without in vitro affinity maturation. As fully human antibodies of outstanding potency and consistent manufacturability, SIMPLE Antibody?-based products come with greatly reduced development risk.

The SIMPLE Antibody? platform is protected by patents with broad claims and freedom to address any disease target of interest.

Since our establishment in 2008, our capabilities and potential have attracted €44 million from leading life science investors and €4.1 million in non-dilutive grants.

In January 2011, we signed our first strategic partnership with Eli Lilly & Company, for the discovery and development of novel human antibodies.